FDA Panel Backs BPC-157 and Five Other Peptides for Pharmacy Compounding July 24

An FDA advisory committee voted narrowly on July 23 and 24 to recommend six unapproved peptides, including BPC-157, be added to a list of substances that compounding pharmacies can legally prepare. The 14-member panel voted 8-6 for BPC-157, KPV and TB-500, and 7-5 for MOTS-c, with one additional vote approving Epitalon and Semax. Health Secretary Robert F. Kennedy Jr. has publicly backed loosening peptide restrictions, but FDA career scientists unanimously opposed all six compounds, citing lack of clinical trial data and safety concerns including potential heart toxicity and cancer risk.

Why the FDA panel voted to expand peptide access

The panel’s majority sided with the peptide industry’s argument that regulating these compounds through licensed pharmacies would reduce harm from the unregulated market. Americans are already injecting peptides sourced from overseas manufacturers and sold via Instagram and TikTok, with no quality controls. Proponents argued that FDA approval of compounding would bring these substances under state and federal oversight, ensuring consistent manufacturing standards and proper prescriptions. The panel heard hours of public comment from telehealth firms and compounding pharmacies supporting the move.

What FDA scientists warned about

FDA career reviewers recommended against approving any of the six peptides. They cited insufficient human trial data, inconsistent batch-to-batch recipes, and specific safety risks. Potential adverse effects include heart toxicity, cancer growth encouragement, and massive immune responses. Some peptides had no published human studies at all. Dr. Elizabeth Rebello, an anesthesiologist on the panel who voted no, stated the committee was responding to market demand rather than solid scientific evidence. The FDA’s own scientists unanimously opposed all six compounds.

What happens next and the legal timeline

The advisory committee’s recommendation is non-binding. The FDA is not required to follow it, and any final decision would require a formal rulemaking process lasting eight to twelve months before compounding pharmacies have legal authority to prepare these substances. According to legal experts, the market is conflating three distinct events: removal from a restricted category, the advisory recommendation, and actual placement on the compoundable list following public comment. Health Secretary Kennedy, who oversees the FDA, has expressed support for peptides but has not yet made a final decision.

The six peptides under consideration

BPC-157 is marketed for muscle recovery and tendon healing. TB-500 and KPV are promoted for athletic performance and recovery. MOTS-c is being evaluated for obesity and osteoporosis. Epitalon and Semax are claimed to support longevity and cognitive function. None have undergone large-scale human trials or received FDA approval as drugs. The panel rejected a seventh peptide, emideltide, citing especially weak evidence. It was proposed as an injection to treat narcolepsy and opioid withdrawal but was supported only by a single patient case report and two small, uncontrolled studies.

Final Thoughts

The FDA panel’s narrow vote reflects a clash between market demand and scientific caution. While final approval remains months away and not guaranteed, the recommendation signals a potential shift in how peptides are regulated. Canadian investors and consumers should monitor the formal rulemaking process, as any U.S. decision could influence how these compounds are treated in Canada.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.